exg34217
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2020 (NCT04211714)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Telomerase reverse transcriptaseACTIVATOR
TERT activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05868499 | Phase 1 | Jul 1, 2023 | Elixirgen Therapeutics, Inc., University of Cincinnati |
| NCT04211714 | Phase 1 | Mar 1, 2020 | Elixirgen Therapeutics, Inc., University of Cincinnati |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elixirgen Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2020 |
| University of Cincinnati | Academic/Hospital | 2 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1